<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566445</url>
  </required_header>
  <id_info>
    <org_study_id>GT005-03</org_study_id>
    <nct_id>NCT04566445</nct_id>
  </id_info>
  <brief_title>HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005</brief_title>
  <official_title>HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyroscope Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyroscope Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and efficacy of two doses of&#xD;
      GT005 administered as a single subretinal injection in subjects with geographic atrophy&#xD;
      secondary to age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, outcomes-assessor masked, multicentre, randomised, controlled&#xD;
      study to evaluate the safety and efficacy of two doses of GT005 administered as a single&#xD;
      subretinal injection in subjects with GA secondary to AMD.&#xD;
&#xD;
      The trial includes a screening period of up to 8 weeks and a 96-week study period.&#xD;
&#xD;
      Subjects will be randomised to one of two groups; GT005 or the untreated control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase II, open-label, outcomes-assessor masked, multicentre, randomised, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcome Assessor). The overall objectives of the study are to evaluate the safety and efficacy (anatomical and functional visual outcomes) of two doses of GT005 in genetically defined subjects with GA due to AMD.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of geographic atrophy</measure>
    <time_frame>48 weeks</time_frame>
    <description>The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of geographic atrophy</measure>
    <time_frame>72 weeks and 96 weeks</time_frame>
    <description>The change from baseline to Week 72 and Week 96 in GA area as measured by fundus autofluorescence (FAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability of GT005</measure>
    <time_frame>96 weeks</time_frame>
    <description>Frequency of treatment emergent adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in retinal microstructures on optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in presence of area of nascent GA on OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on retinal anatomical measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in GA morphology on multimodal imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Macular sensitivity as assessed by mesopic microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in BCVA Score via the early treatment for diabetic retinopathy (ETDRS) chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on functional measures</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in low luminance difference (LLD) via the ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on visual function</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in reading performance as assessed by Minnesota low-vision reading test (MNRead) chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on visual function</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in functional reading independence (FRI) index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of GT005 on patient-reported outcomes</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in quality of life measured on the Visual Functioning Questionnaire-25 (VFQ-25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effects of GT005 on the progression of GA, in each genetically defined subgroup(s)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change from baseline to Week 48, Week 72, and Week 96 in GA area as measured by FAF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>GT005 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 60 subjects are planned, with subjects randomised to GT005 Medium Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 60 subjects are planned, with subjects randomised to GT005 High Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Approximately 60 subjects are planned, with subjects randomised to untreated control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT005: Medium Dose</intervention_name>
    <description>The study will test two doses of GT005: Medium Dose and High Dose.</description>
    <arm_group_label>GT005 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT005: High Dose</intervention_name>
    <description>The study will test two doses of GT005: Medium Dose and High Dose.</description>
    <arm_group_label>GT005 High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to give written informed consent&#xD;
&#xD;
          2. Age ≥55 years&#xD;
&#xD;
          3. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by&#xD;
             the Investigator, and a diagnosis of AMD in the contralateral eye&#xD;
&#xD;
          4. GA lesion(s) within an acceptable size on FAF, in the study eye&#xD;
&#xD;
          5. The GA lesion in the study eye must reside completely within the FAF image&#xD;
&#xD;
          6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye&#xD;
&#xD;
          7. Have a BCVA of ≥24 letters (6/95 or 20/320 Snellen acuity equivalent), using ETDRS&#xD;
             charts, in the study eye&#xD;
&#xD;
          8. Meet one of the pre-specified AMD genetic subgroup criteria&#xD;
&#xD;
          9. Able to attend all study visits and complete the study procedures&#xD;
&#xD;
         10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks&#xD;
             prior to randomisation (not required for postmenopausal women) or provide&#xD;
             documentation of being surgically sterilised&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Carriers of excluded genetic variants&#xD;
&#xD;
          2. Have a history, or evidence, of CNV in the study eye&#xD;
&#xD;
          3. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in the&#xD;
             study eye&#xD;
&#xD;
          4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the&#xD;
             study eye&#xD;
&#xD;
          5. History of intraocular surgery in the study eye within 12 weeks prior to Visit 1&#xD;
&#xD;
          6. Have clinically significant cataract that may require surgery during the study period&#xD;
             in the study eye&#xD;
&#xD;
          7. Presence of moderate to severe glaucomatous optic neuropathy, uncontrolled intraocular&#xD;
             pressure (IOP), despite use of two or more topical agents; or a history of&#xD;
             glaucoma-filtering or valve surgery&#xD;
&#xD;
          8. Axial myopia of greater than -8 diopters in the study eye&#xD;
&#xD;
          9. Have received any investigational product for the treatment of GA within the past 6&#xD;
             months or 5 half-lives (whichever is longer), other than nutritional supplements such&#xD;
             as the age-related eye disease study (AREDS) formula&#xD;
&#xD;
         10. Have received a gene or cell therapy at any time.&#xD;
&#xD;
         11. Have a contraindication to the protocol specified corticosteroid regimen&#xD;
&#xD;
         12. Are unwilling to use two forms of contraception (one of which being a barrier method)&#xD;
             for 90 days post-dosing, if relevant&#xD;
&#xD;
         13. Active malignancy within the past 12 months, except for appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with&#xD;
             a stable prostate-specific antigen (PSA) ≥ 12 months&#xD;
&#xD;
         14. Have any other significant ocular or non-ocular medical or psychiatric condition&#xD;
             which, in the opinion of the Investigator, may either put the subject at risk or may&#xD;
             influence the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gyroscope Gyroscope Therapeutics</last_name>
    <phone>+441438532142</phone>
    <phone_ext>+441438532142</phone_ext>
    <email>clinicaltrials@gyroscopetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retinal Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest Retina Research Center</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rand Eye Institute</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VitreoRetinal Associates of Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Retina Macula Associates PC</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute Northside</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates PA</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Retina</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harkness Eye Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western NY</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Retina</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute - OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wills Eye Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palmetto Eye</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SE Retina Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Center Northwest</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Melbourne - The Centre for Eye Research Australia (CERA)</name>
      <address>
        <city>Melbourne E.</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Paradis Monticelli</name>
      <address>
        <city>Marseille</city>
        <state>Alpes-Cote d'Azur</state>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital F. Mitterrand</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne-Franche-Comté</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wurttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Augenklinik</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat Del Vallès</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Baviera</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad De Madrid</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Vision Clinic</name>
      <address>
        <city>London</city>
        <zip>W1G 7LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry age-related macular degeneration</keyword>
  <keyword>Geographic atrophy</keyword>
  <keyword>Retinal disease</keyword>
  <keyword>Eye disease</keyword>
  <keyword>Retinal degeneration</keyword>
  <keyword>Macular atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

